li-ting Qin

Mrs. li-ting Qin


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
SLSong-Wu Liang
Song-Wu Liang
GCGang Chen
Gang Chen
YLYi-Ge Luo
Yi-Ge Luo
PCPeng Chen
Peng Chen
JGJin-Han Gu
Jin-Han Gu
JCJiabo Chen
Jiabo Chen
Liang SW, et al. Ann Surg Treat Res. 2020 Aug;99(2):118-126. https://doi.org/10.4174/astr.2020.99.2.118

5 September 2022 in Genetics Research
Verified
Journal Article
Open access
PDF file
JWJia-Ying Wen
Jia-Ying Wen
GCGang Chen
Gang Chen
JLJian-Di Li
Jian-Di Li
JLJia-yuan Luo
Jia-yuan Luo
JHJuan He
Juan He
LQli-ting Qin
li-ting Qin
The clinical significance and potential targets of miR-150-5p have not been elucidated in nasopharyngeal carcinoma (NPC). The pooled analysis based on 539 NPC samples and 75 non-NPC nasopharyngeal samples demonstrated that the expression of miR-150-5p was down-regulated in NPC, with the area under the curve being 0.89 and the standardized mean difference being −0.66. Subsequently, we further screened the differentially expressed genes (DEGs) of 14 datasets, including 312 NPC samples and 70 non-NPC nasopharyngeal samples. After the DEGs were narrowed down with the predicted targets from the miRWalk database, 1316 prospective target genes of miR-150-5p were identified. The enrichment analysis suggested that “pathways in cancer” was the most significant pathway. Finally, six hub genes of “pathways in cancer”, including EGFR, TP53, HRAS, CCND1, CDH1, and FGF2, were screened out through the STRING database. In conclusion, the down-regulation of miR-150-5p modulates the tumorigenesis and progression of NPC.

25 February 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
JWJia-Ying Wen
Jia-Ying Wen
LQli-ting Qin
li-ting Qin
GCGang Chen
Gang Chen
HHHe-Qing Huang
He-Qing Huang
MSMing-Jun Shen
Ming-Jun Shen
JLJia-yuan Luo
Jia-yuan Luo
Background. This study was aimed at elucidating the molecular biological mechanisms of microRNA-1 (miR-1) in nasopharyngeal carcinoma (NPC). Method. In this study, we performed a pooled analysis of miR-1 expression data derived from public databases, such as GEO, ArrayExpress, TCGA, and GTEx. The miRWalk 2.0 database, combined with the mRNA microarray datasets, was used to screen the target genes, and the genes were then subjected to Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analysis using the DAVID 6.8 database. We then used the STRING 11.0 database and Cytoscape 3.80 software to construct a protein-protein interaction (PPI) network for screening hub genes. Immunohistochemistry (IHC) was further used to validate the expression of hub genes. Finally, potential therapeutic agents for NPC were screened by the Connectivity Map (cMap) database. Results. Pooled analysis showed that miR-1 expression was significantly decreased in NPC ( ; ). The summary receiver operating characteristic curve suggested that miR-1 had a good ability to distinguish cancerous tissues from noncancerous tissues ( ). The results of GO analysis focused on mitotic nuclear division, DNA replication, cell division, cell adhesion, extracellular space, kinesin complex, and extracellular matrix (ECM) structural constituent. The KEGG analysis suggested that the target genes played a role in key signaling pathways, such as cell cycle, focal adhesion, cytokine-cytokine receptor interaction, ECM-receptor interaction, and PI3K/Akt signaling pathway. The PPI network suggested that cyclin-dependent kinase 1 (CDK1) was the hub gene, and the CDK1 protein was subsequently confirmed to be significantly upregulated in NPC tissues by IHC. Finally, potential therapeutic drugs, such as masitinib, were obtained by the cMap database. Conclusion. miR-1 may play a vital part in NPC tumorigenesis and progression by regulating focal adhesion kinase to participate in cell mitosis, regulating ECM degradation, and affecting the PI3K/Akt signaling pathway. miR-1 has the potential to be a therapeutic target for NPC.

27 September 2022 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
SHSi-Wei Huang
Si-Wei Huang
GCGang Chen
Gang Chen
JLJian-Di Li
Jian-Di Li
LQli-ting Qin
li-ting Qin
ZHZhi-Guang Huang
Zhi-Guang Huang
JLJia-yuan Luo
Jia-yuan Luo
Background. Currently, the benefits of nasopharyngeal carcinoma (NPC) therapy are limited, and it is necessary to further explore possible therapeutic targets. Aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) has been extensively studied in other cancer species, but little has been explored in NPC. The aim of this study was to verify the expression level of ARNT2 and its underlying mechanism in NPC. Methods. Datasets containing ARNT2 mRNA expression levels were retrieved and collected from various databases to explore the expression status of ARNT2 in NPC. ARNT2-related coexpressed genes, differential expressed genes, and target genes were obtained for functional enrichment analysis. The potential target gene of ARNT2 and their regulatory relationship were studied through ChIP-seq data. CIBERSORTx was used to assess the immune infiltration of NPC, and the association with ARNT2 expression was calculated through correlation analysis. Results. ARNT2 was upregulated and possessed an excellent discriminatory capability in NPC samples. ARNT2 positively correlated target genes were clustered in pathways in cancer, while negatively correlated target genes were enriched in immune-related pathway. The ChIP-seq information of ARNT2 and histone showed that prostaglandin-endoperoxide synthase 2 (PTGS2) was a potential target gene of ARNT2. CIBERSORTx revealed the immunity status in NPC, and ARNT2 expression was correlated with infiltration of five immune cells. Conclusions. ARNT2 is overexpressed in NPC and may regulate PTGS2 to participate in the cancer process. ARNT2 serves as a key oncogenic target in NPC patients.